Actively Recruiting
Anti-inflammatory Therapy for Recurrent In-stent Restenosis
Led by Fu Wai Hospital, Beijing, China · Updated on 2025-08-08
252
Participants Needed
4
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is aimed at making a comparison of the safety and efficacy of standard drug therapy (control group), standard drugs combined with lose-dose colchicine therapy (colchicine group) and standard drug combined with prednisone therapy (prednisone group) in patients with coronary heart disease who suffered from recurrent In-stent restenosis (RISR).
CONDITIONS
Official Title
Anti-inflammatory Therapy for Recurrent In-stent Restenosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with coronary artery disease aged 18 years or older
- At least one coronary artery lesion with recurrent in-stent restenosis (narrowing of 50% or more inside or near a stent, with two or more ISR occurrences)
- Planned treatment for recurrent in-stent restenosis lesions
- Able to accept standard secondary prevention drugs including dual antiplatelet therapy and statins
- Willing to participate, complete follow-up, and sign informed consent approved by the ethics committee
You will not qualify if you...
- Unknown previous interventional treatment details
- ISR caused by poor stent adhesion, incomplete dilation, or stent fracture as determined by intracavitary imaging
- Diagnosed vascular inflammatory or connective tissue diseases involving coronary arteries (e.g., arteritis, Behcet's disease, lupus)
- Use of immunosuppressive drugs including glucocorticoids within the past 30 days
- Contraindications to prednisone or colchicine such as serious infections (active infection, hepatitis B or C, AIDS), blood disorders (thrombocytopenia, severe anemia, leukemia), uncontrolled diabetes, severe liver or kidney damage, active peptic ulcer or gastrointestinal bleeding, severe osteoporosis with past fractures, inflammatory bowel disease or chronic diarrhea
- History of malignant tumors within past 3 years
- Cognitive impairment
- Unwillingness to participate or follow up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 10000
Actively Recruiting
2
Beijing Friendship Hospital
Beijing, Beijing Municipality, China, 10000
Not Yet Recruiting
3
Beijing Luhe Hospital
Beijing, Beijing Municipality, China, 10000
Actively Recruiting
4
Fuwai Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
H
Haiyan Qian
CONTACT
Z
Zhiyao Wei
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here